Recursion Pharmaceuticals Inc (NASDAQ: RXRX) kicked off on Friday, down -1.37% from the previous trading day, before settling in for the closing price of $4.39. Over the past 52 weeks, RXRX has traded in a range of $3.79-$12.36.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 112.62% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 15.09%. With a float of $307.84 million, this company’s outstanding shares have now reached $399.15 million.
In terms of profitability, gross margin is -0.08%, operating margin of -960.64%, and the pretax margin is -962.73%.
Recursion Pharmaceuticals Inc (RXRX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Recursion Pharmaceuticals Inc is 24.27%, while institutional ownership is 59.28%. The most recent insider transaction that took place on Mar 27 ’25, was worth 836,987. In this transaction Chief Executive Officer of this company sold 138,574 shares at a rate of $6.04, taking the stock ownership to the 1,117,450 shares. Before that another transaction happened on Mar 27 ’25, when Company’s Officer proposed sale 138,574 for $6.04, making the entire transaction worth $836,987.
Recursion Pharmaceuticals Inc (RXRX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 15.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.85% during the next five years compared to -35.28% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Take a look at Recursion Pharmaceuticals Inc’s (RXRX) current performance indicators. Last quarter, stock had a quick ratio of 4.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 29.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.78, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.22 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Let’s dig in a bit further. During the last 5-days, its volume was 26.22 million. That was better than the volume of 23.18 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 10.13%. Additionally, its Average True Range was 0.49.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 6.30%, which indicates a significant decrease from 11.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 99.03% in the past 14 days, which was lower than the 106.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.66, while its 200-day Moving Average is $6.72. However, in the short run, Recursion Pharmaceuticals Inc’s stock first resistance to watch stands at $4.54. Second resistance stands at $4.74. The third major resistance level sits at $4.86. If the price goes on to break the first support level at $4.22, it is likely to go to the next support level at $4.10. Assuming the price breaks the second support level, the third support level stands at $3.90.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
The company with the Market Capitalisation of 1.76 billion has total of 401,991K Shares Outstanding. Its annual sales at the moment are 58,840 K in contrast with the sum of -463,660 K annual income. Company’s last quarter sales were recorded 4,550 K and last quarter income was -178,910 K.
